Key facts
- Everself’s last known valuation is $30.0M (May 2025).
- It has raised $11.1M; the latest was Seed Round ($11.1M) in May 2025.
- Notable investors include 500 Global, BrandProject, SeaX Ventures.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Everself
- ·The full record, as it builds
Funding rounds
No funding rounds for Everself are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Everself
Operator of a weight loss medication company intended for clinical obesity management. The company's platform offers a one-time endoscopic procedure to reduce stomach size, supported by a year-long concierge care program that includes access to physicians, nurse practitioners, registered dietitians, coaches, and a digital app for ongoing support, enabling individuals seeking weight loss to achieve sustainable results without surgery, scars, or injections, and to benefit from continuous medical guidance and habit-building resources.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2023
- Employees
- 21
- Website
- everself.com/
- Ownership
- Privately Held (backing)
Everself doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Everself shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Everself in its N-PORT filings yet. We sweep new filings monthly.